MyFinsight
Home
Blog
About
Contact
Download
Download image
Accounts receivable
-$335K
Non-cash operating lease
expense
$310K
Stock-based compensation
$288K
Depreciation and
amortization
$219K
Interest expense on
related party note...
$145K
Change in inventory
reserve
$45K
Net cash provided by
operating activities
$8K
Canceled cashflow
$1,334K
Net decrease in cash
-$237K
Canceled cashflow
$8K
Net loss
-$418K
Inventories
$387K
Operating lease
liabilities
-$354K
Accrued liabilities
-$99K
Prepaid expenses and
other current assets
$58K
Accounts payable
-$18K
Product sales
$9,100K
Net cash used in
financing activities
-$200K
Net cash used in
investing activities
-$45K
Loss from operations
-$267K
Other expense, net
-$151K
Canceled cashflow
$9,100K
Principal repayment on
note payable from...
$200K
Purchases of property and
equipment
$43K
Payments for patent
licenses
$2K
Total operating
expenses
$9,367K
Cost of sales
$4,033K
General and
administrative
$3,532K
Selling and marketing
$1,118K
Research and development
$684K
Back
Back
Cash Flow
source: myfinsight.com
International Stem Cell CORP (ISCO)
International Stem Cell CORP (ISCO)